LINC00587: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

Target Name: LINC00587

NCBI ID: G414319

LINC00587

Other Name(s): C9orf107 | bA785H23.1 | Long intergenic non-protein coding RNA 587 | long intergenic non-protein coding RNA 587

LINC00587: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

LINC00587 (C9orf107) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and biology have made it an attractive target for researchers to study, and various studies have shown promise in using LINC00587 as a therapeutic approach.

LINC00587 is a small non-coding RNA molecule that is approximately 200 nucleotides long. It is expressed in a variety of tissues and cells throughout the body and is involved in the regulation of various gene expression processes. One of the most interesting aspects of LINC00587 is its unique structure. It has a stem-loop structure, which is a type of RNA structure that is composed of a series of alternating double-stranded regions that are connected by a loop. This unique structure allows LINC00587 to have a variety of different ways of interacting with other molecules, such as proteins or small molecules.

One of the key features of LINC00587 is its ability to interact with the protein PDGF-BB. PDGF-BB is a protein that is involved in cell signaling and growth, and it has been shown to play a role in the development and progression of various diseases, including cancer. LINC00587 has been shown to bind to PDGF-BB and to inhibit its activity, which could be a potential therapeutic approach for cancer treatment.

Another interesting aspect of LINC00587 is its expression in cancer cells. Cancer cells have a unique ability to survive and grow in an environment that is hostile to the body's immune system, and they often have a variety of mechanisms that allow them to evade detection and treatment. LINC00587 has been shown to be expressed in various types of cancer cells and has been shown to play a role in the development and progression of these diseases. This suggests that LINC00587 could be a useful biomarker for cancer and that it could be a potential drug target.

In addition to its potential as a drug target, LINC00587 has also been shown to have a variety of other biological functions. For example, it has been shown to play a role in the regulation of cell cycle progression, and it has been shown to interact with the protein T-cell receptor. T-cell receptor is a protein that is involved in the immune response and has been shown to play a role in the development of various diseases, including cancer. LINC00587 has been shown to interact with T-cell receptor and to regulate its activity, which could be another potential therapeutic approach for cancer treatment.

Overall, LINC00587 is a unique and fascinating molecule that has a variety of different biological functions. Its unique structure and expression in various types of cells and tissues make it an attractive target for research and therapeutic development. Further studies are needed to fully understand the role of LINC00587 in the development and progression of various diseases, including cancer.

Protein Name: Long Intergenic Non-protein Coding RNA 587

The "LINC00587 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00587 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets